Welcome, John McCulloch!

We are pleased to welcome John McCulloch to the UHN Commercialization Team! John joins us in the role of Principal, Commercialization Investment Programs.  

In this role, John will lead and expand UHN’s internal commercialization funding programs, including the Accelerator Fund, created in 2024 in partnership with the Princess Margaret Cancer Foundation and UHN Foundation. The Accelerator Fund is a key strategic vehicle that supports UHN’s commitment to translating our world-class science into products and treatments with the potential to improve patient care globally. Part of bridging the gap between initial discovery and patient impact, the Accelerator Fund provides capital, resources and strategic support to help de-risk commercially promising technologies toward external investment, partnership and clinical impact.  

John brings deep experience at the intersection of research, investment and industry. Throughout his career, John has worked closely with researchers, universities, hospitals, start-ups, biotech companies, pharmaceutical partners, and investors alike. He has completed over 30 life sciences investments including the acquisition of royalty streams in blockbuster medicines such as Humira, Remicade, Stelara, Eylea and Zytiga.  

He has also supported Ontario’s life sciences ecosystem by advising numerous start-ups on business strategy and fundraising, and by serving as a reviewer for commercialization funding programs that have enabled companies to secure capital and scale their innovations.

John is passionate about advancing medical discoveries into meaningful solutions for unmet clinical needs. He holds a PhD in Immunology from the University of London and is a Certified Licensing Professional (CLP). His experience bridging life sciences research and industry will be an important asset as UHN continues to strengthen its translational and clinical research pipeline.

Please join us in welcoming John to the team!

‍

‍